P32 MAJESTEC-1: CORRELATIVE ANALYSES OF TECLISTAMAB, A B-CELL MATURATION ANTIGEN (BCMA) X CD3 BISPECIFIC ANTIBODY, IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM)
Niels W.C.J. van de Donk(Oncode Institute), Raluca Verona(Centre Hospitalier Universitaire de Nantes), Lei Wu(Janssen (United States)), C. Davis(Janssen (United States)), Judith D. Goldberg(New York University), Saad Z. Usmani(Memorial Sloan Kettering Cancer Center), Tineke Casneuf(Argenx (Belgium)), Danielle Trancucci(Centre Hospitalier Universitaire de Nantes), Shun Xin Wang Lin(Centre Hospitalier Universitaire de Nantes), Diana Cortés‐Selva(Johnson & Johnson (United States)), Deeksha Vishwamitra(Janssen (United States)), Rachel Kobos(Centre Hospitalier Universitaire de Nantes), Arnob Banerjee(Johnson & Johnson (United States)), Olivia Lau(Janssen (United States)), Nizar J. Bahlis(Institute of Cancer Research), Suzette Girgis(Centre Hospitalier Universitaire de Nantes), Tara Stephenson(Centre Hospitalier Universitaire de Nantes), Clarissa Uhlar(University of Pennsylvania), Leen van Steenbergen, Lixia Pei(Janssen (United States)), Sarah Stein(Harvard Pilgrim Health Care), Tatiana Perova(Janssen (United States)), Philippe Moreau(Centre National de la Recherche Scientifique), Elena Ramos
Cited by 7
Related Papers
Revised International Staging System for Multiple Myeloma: A Report From International Myeloma Working Group
|Journal of Clinical Oncology|2015|2.2k
Definition of organ involvement and treatment response in immunoglobulin light chain amyloidosis (AL): A consensus opinion from the 10th International Symposium on Amyloid and Amyloidosis
|American Journal of Hematology|2005|1.4k
Teclistamab in Relapsed or Refractory Multiple Myeloma
|New England Journal of Medicine|2022|1.2k
Serum amyloid A, the major vertebrate acute‐phase reactant
|European Journal of Biochemistry|1999|1.1k